Small breast tumors might need more treatment: study
WASHINGTON (Reuters) - Little breast tumors that seemed cured after surgery are more likely to come back if they are the type known as HER2 positive, U.S. researchers reported on Friday.
They said women who have these types of tumors may need extra treatment with drugs such as Genentech Inc.’s Herceptin — which is not standard practice now.
“Most physicians do not treat these small tumors with Herceptin,” Dr. Ana M. Gonzalez-Angula of the M.D. Anderson Cancer Center in Houston, who led the study, told reporters in a telephone briefing.
After five years, 23 percent of patients with tiny tumors one cm (half an inch) or smaller whose cancer was HER2 positive had tumors come back after surgery, Gonzalez-Angula told the San Antonio Breast Cancer Conference.
Her team looked at more than 1,300 women between 1990 and 2003. Ten percent had HER2 tumors and they had a much higher likelihood the cancer would come back than those with the more common estrogen receptor positive tumors or those with so-called triple negative tumors.
These three types of tumor each have a different mutation that drives the cancer. Estrogen receptor positive breast tumors are the easiest to treat, with a range of drugs that affect the hormone.
The women, with an average age of 57, had 2.68 times the risk their cancer would come back after surgery if they had HER2-positive tumors than the other patients, Gonzalez-Angula told the meeting.
HER2-positive tumors had been more difficult to treat but Herceptin, known generically as trastuzumab, is a genetically engineered antibody — an immune system molecule — that homes in on that particular mutation.
(Reporting by Maggie Fox, Editing by Jackie Frank)
--------------------------------------------------------------------------------------------Related Posts:
NEW YORK (Reuters Health) - Rather than protecting against all breast cancers, high levels of soy food consumption appears to specifically reduce the risk of estrogen receptor (ER)-positive tumors and human epidermal growth factor receptor 2 (HER2)-negative tumors, Japanese researchers report in the International Journal of Cancer. Dr. Takeshi Suzuki, at Aichi Cancer Center Research Institute
Full Post: Soy reduces breast cancer risk by receptor status
--------------------------------------------------------------------------------------------
NEW YORK (Reuters Health) - Rather than protecting against all breast cancers, high levels of soy food consumption appears to specifically reduce the risk of estrogen receptor (ER)-positive tumors and human epidermal growth factor receptor 2 (HER2)-negative tumors, Japanese researchers report in the International Journal of Cancer. Dr. Takeshi Suzuki, at Aichi Cancer Center Research Institute
Full Post: Soy reduces breast cancer risk by receptor status
--------------------------------------------------------------------------------------------
WASHINGTON (Reuters) - A new type of imaging compound can literally light up spreading cancer cells and may offer a way to track the deadly spread of the disease, Japanese and U.S. researchers reported on Sunday. They used the new compound to monitor the spread of breast and ovarian cancer cells in living mice, using a
Full Post: Compound lights up spreading cancer cells
--------------------------------------------------------------------------------------------
WASHINGTON (Reuters) - Certain breast cancer survivors who load up on fruits and vegetables, eating far more than current U.S. guidelines, can slash their risk the tumors will come back by nearly a third, according to a U.S. study released on Monday. The finding only held for women who did not have hot flashes after their
Full Post: Fruits, veggies slash breast cancer risk: U.S. study
--------------------------------------------------------------------------------------------
NEW YORK (Reuters Health) - Data from the Women’s Health Initiative Observational Study show that higher than normal insulin levels are an independent risk factor for breast cancer. Study investigators, led by Dr. Marc J. Gunter at Albert Einstein College of Medicine in the Bronx, New York, examined the association between breast cancer and blood parameters
Full Post: High insulin levels may increase breast cancer risk